These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9832350)

  • 1. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava).
    Uebelhack R; Franke L; Schewe HJ
    Pharmacopsychiatry; 1998 Sep; 31(5):187-92. PubMed ID: 9832350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine Oxidase Inhibition by Kavalactones from Kava (Piper Methysticum).
    Prinsloo D; van Dyk S; Petzer A; Petzer JP
    Planta Med; 2019 Oct; 85(14-15):1136-1142. PubMed ID: 31539917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro.
    Weiss J; Sauer A; Frank A; Unger M
    Drug Metab Dispos; 2005 Nov; 33(11):1580-3. PubMed ID: 16051732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of various Piper methysticum cultivars with CNS receptors in vitro.
    Dinh LD; Simmen U; Bueter KB; Bueter B; Lundstrom K; Schaffner W
    Planta Med; 2001 Jun; 67(4):306-11. PubMed ID: 11458444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kava-kava preparations--alternative anxiolytics].
    Nowakowska E; Ostrowicz A; Chodera A
    Pol Merkur Lekarski; 1998 Mar; 4(21):179-180a. PubMed ID: 9640076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [3H]-monoamine uptake inhibition properties of kava pyrones.
    Seitz U; Schüle A; Gleitz J
    Planta Med; 1997 Dec; 63(6):548-9. PubMed ID: 9434608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition of carboxylesterase 1 by Kava (Piper methysticum) Kavalactones.
    Melchert PW; Qian Y; Zhang Q; Klee BO; Xing C; Markowitz JS
    Chem Biol Interact; 2022 Apr; 357():109883. PubMed ID: 35278473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets.
    Gleitz J; Beile A; Wilkens P; Ameri A; Peters T
    Planta Med; 1997 Feb; 63(1):27-30. PubMed ID: 9063093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm.
    Smith KK; Dharmaratne HR; Feltenstein MW; Broom SL; Roach JT; Nanayakkara NP; Khan IA; Sufka KJ
    Psychopharmacology (Berl); 2001 Apr; 155(1):86-90. PubMed ID: 11374340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro.
    Mathews JM; Etheridge AS; Valentine JL; Black SR; Coleman DP; Patel P; So J; Burka LT
    Drug Metab Dispos; 2005 Oct; 33(10):1555-63. PubMed ID: 16033948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes.
    Zou L; Henderson GL; Harkey MR; Sakai Y; Li A
    Phytomedicine; 2004; 11(4):285-94. PubMed ID: 15185840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kava: a comprehensive review of efficacy, safety, and psychopharmacology.
    Sarris J; LaPorte E; Schweitzer I
    Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A UHPLC-UV Method Development and Validation for Determining Kavalactones and Flavokavains in
    Tang Y; Fields C
    Molecules; 2019 Mar; 24(7):. PubMed ID: 30934989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kava does not display metabolic toxicity in a homogeneous cellular assay.
    Zou L; Harkey MR; Henderson GL; Dike LE
    Planta Med; 2004 Apr; 70(4):289-92. PubMed ID: 15095141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals].
    Holm E; Staedt U; Heep J; Kortsik C; Behne F; Kaske A; Mennicke I
    Arzneimittelforschung; 1991 Jul; 41(7):673-83. PubMed ID: 1772452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of genuine kavapyrone enantiomers on the GABA-A binding site.
    Boonen G; Häberlein H
    Planta Med; 1998 Aug; 64(6):504-6. PubMed ID: 9776662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kavalactones fail to inhibit alcohol dehydrogenase in vitro.
    Anke J; Fu S; Ramzan I
    Phytomedicine; 2006 Feb; 13(3):192-5. PubMed ID: 16428028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrospray high performance liquid chromatography-mass spectrometry in phytochemical analysis of kava (Piper methysticum) extract.
    He XG; Lin LZ; Lian LZ
    Planta Med; 1997 Feb; 63(1):70-4. PubMed ID: 17252331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
    Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
    Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells.
    Whittaker P; Clarke JJ; San RH; Betz JM; Seifried HE; de Jager LS; Dunkel VC
    Food Chem Toxicol; 2008 Jan; 46(1):168-74. PubMed ID: 17822821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.